After clinical trial rejection and no word on technology transfer, Olix rides a rollercoaster amid Peptron shock
Predicted impact: Low
Clinical trial rejection and unannounced technology transfer; vague, no size given, small relative to news flow.
OliX Pharmaceuticals올릭스
226950 · KOSDAQ · ₩226950 · 올릭스
₩90,600▼ ₩5,500 (5.72%)End-of-day · Oct 27, 2026 · End-of-day prices.
[Today's IR] Hyundai Rotem, Allixpharma, Canaphytetherapeutics and Others
Predicted impact: Low
Olix Plunges 14% and Lockit Healthcare Hits 52-Week Low as Clinical Trial Application Rejected [Bio Market Briefing]
Predicted impact: Medium· Actual: −10.0% vs sector, volume 0.6× normal (5 trading days)
Clinical trial application rejection at a different company; Rokit impact unclear, only a 52-week low noted.
Also known as: OliX Pharmaceuticals / 올릭스 / 226950 / KRX:226950
Source: KRX statistical information